Page 2 - Cortexyme Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cortexyme inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cortexyme Inc Today - Breaking & Trending Today

Cortexyme (NASDAQ:CRTX) Shares Cross Above 200-Day Moving Average of $1.18

Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.18 and traded as high as $1.20. Cortexyme shares last traded at $1.15, with a volume of 36,188 shares. Cortexyme Price Performance The company has a market […] ....

Jacobs Levy Equity Management Inc , Cortexyme Company Profile , Blackrock Inc , Jpmorgan Chase Co , Vanguard Group Inc , Cortexyme Inc , Get Free Report , Levy Equity Management , State Street Corp , Street Corp , Cortexyme Daily , Nasdaq Crtx ,

Quince Therapeutics, Inc. (NASDAQ:QNCX) Director Buys $22,773.54 in Stock

Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) Director David Lamond bought 22,327 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was bought at an average price of $1.02 per share, for a total transaction of $22,773.54. Following the completion of the purchase, the director now directly owns 2,302,291 […] ....

David Lamond , Quince Therapeutics Company Profile , Cortexyme Inc , Renaissance Technologies , Capital Management , Millennium Management , Securities Exchange Commission , Blackrock Inc , Quince Therapeutics Inc , Quince Therapeutics , Get Free Report , Director David Lamond , Exchange Commission , Sigma Investments , Quince Therapeutics Daily , Nasdaq Qncx , Insider Trading , Nsider Trades ,

Quince Therapeutics, Inc. (NASDAQ:QNCX) Director David Lamond Acquires 19,123 Shares

Quince Therapeutics, Inc. (NASDAQ:QNCX) Director David Lamond Acquires 19,123 Shares
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

United States , David Lamond , Intellectus Partners , Quince Therapeutics Inc , Securities Exchange Commission , Geode Capital Management , Cortexyme Inc , Quince Therapeutics , Get Free Report , Director David Lamond , Exchange Commission , Wisconsin Investment Board , Quince Therapeutics Daily ,

Quince Therapeutics, Inc. (NASDAQ:QNCX) Director David Lamond Purchases 19,123 Shares

Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) Director David Lamond bought 19,123 shares of the firm’s stock in a transaction on Tuesday, December 5th. The shares were purchased at an average cost of $1.01 per share, with a total value of $19,314.23. Following the completion of the transaction, the director now owns 2,241,418 shares […] ....

David Lamond , Capital Management , Quince Therapeutics Inc , Geode Capital Management , Millennium Management , Cortexyme Inc , Renaissance Technologies , Quince Therapeutics , Get Free Report , Director David Lamond , Sigma Investments , Quince Therapeutics Daily , Nasdaq Qncx , Insider Trading , Nsider Trades ,

Insider Buying: Quince Therapeutics, Inc. (NASDAQ:QNCX) Director Purchases 19,123 Shares of Stock

Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) Director David Lamond bought 19,123 shares of the stock in a transaction on Thursday, December 7th. The stock was purchased at an average price of $1.01 per share, with a total value of $19,314.23. Following the completion of the acquisition, the director now directly owns 2,279,664 shares […] ....

David Lamond , Intellectus Partners , Quince Therapeutics Inc , Geode Capital Management , Blackrock Inc , Renaissance Technologies , Cortexyme Inc , Securities Exchange Commission , Quince Therapeutics , Get Free Report , Director David Lamond , Exchange Commission , Capital Management , Quince Therapeutics Daily , Nasdaq Qncx , Insider Trading , Nsider Trades ,